Researchers have identified critical antibody binding sites on the JC polyomavirus (JCPyV), a breakthrough that could pave the way for the first effective treatments and vaccines against the virus responsible for progressive multifocal leukoencephalopathy (PML), a rare but usually fatal brain disease affecting people with severely weakened immune systems. The findings were published in the journal PNAS.
The international study, led by researchers at the University of Tübingen in collaboration with Brown University and Universitätsspital Zürich, focused on understanding how the human immune system successfully neutralizes the virus in the small number of patients who survive PML. Scientists identified specific regions on the viral capsid where highly specialized neutralizing antibodies bind, preventing the virus from entering healthy cells and stopping the infection from spreading.
JC polyomavirus is widespread in the general population and typically remains harmless. However, in individuals with advanced HIV infection, organ transplant recipients, cancer patients, or those receiving powerful immunosuppressive therapies, the virus can spread to the central nervous system and cause PML. Since there are currently no approved antiviral treatments for the disease, it is often fatal.
Using high-resolution structural analysis, the researchers examined how the most effective antibodies recognize and bind to the virus. They also discovered that the virus can develop genetic mutations at these antibody binding sites, allowing it to escape immune recognition. Understanding these escape mechanisms provides valuable insights for designing next-generation therapeutic antibodies that remain effective even against mutated viral strains.
The findings also have broader implications beyond JC polyomavirus. Because the closely related BK polyomavirus shares similar structural features, researchers believe that future vaccines or antibody-based therapies could offer protection against both viruses. Such dual-targeted approaches may significantly improve the prevention and treatment of severe polyomavirus infections in high-risk, immunocompromised patients.
